X

Download Hypertension PowerPoint Presentation

SlidesFinder-Advertising-Design.jpg

Login   OR  Register
X


Iframe embed code :



Presentation url :

Home / Health & Wellness / Health & Wellness Presentations / Hypertension PowerPoint Presentation

Hypertension PowerPoint Presentation

Ppt Presentation Embed Code   Zoom Ppt Presentation

PowerPoint is the world's most popular presentation software which can let you create professional Hypertension powerpoint presentation easily and in no time. This helps you give your presentation on Hypertension in a conference, a school lecture, a business proposal, in a webinar and business and professional representations.

The uploader spent his/her valuable time to create this Hypertension powerpoint presentation slides, to share his/her useful content with the world. This ppt presentation uploaded by onlinesearch in Health & Wellness ppt presentation category is available for free download,and can be used according to your industries like finance, marketing, education, health and many more.

About This Presentation

Hypertension Presentation Transcript

Slide 1 - Kieran McGlade Nov 2001 Department of General Practice QUB Hypertension
Slide 2 - Kieran McGlade Nov 2001 Department of General Practice QUB Aetiology of Hypertension Primary – 90-95% of cases – also termed “essential” of “idiopathic” Secondary – about 5% of cases Renal or renovascular disease Endocrine disease Phaeochomocytoma Cusings syndrome Conn’s syndrome Acromegaly and hypothyroidism Coarctation of the aorta Iatrogenic Hormonal / oral contraceptive NSAIDs
Slide 3 - Kieran McGlade Nov 2001 Department of General Practice QUB This left ventricle is very thickened (slightly over 2 cm in thickness), but the rest of the heart is not greatly enlarged. This is typical for hypertensive heart disease. The hypertension creates a greater pressure load on the heart to induce the hypertrophy.
Slide 4 - Kieran McGlade Nov 2001 Department of General Practice QUB The left ventricle is markedly thickened in this patient with severe hypertension that was untreated for many years. The myocardial fibers have undergone hypertrophy.
Slide 5 - Kieran McGlade Nov 2001 Department of General Practice QUB H O T Hypertension Optimal Treatment Largest intervention trial in hypertension. Published in 1998 Conducted in General Practice. 18,790 patients in 26 countries Followed up for an average of 3.8 years
Slide 6 - Kieran McGlade Nov 2001 Department of General Practice QUB H O T Findings Lowest incidence of major CV events occurred at a mean achieved DBP of 83 mmhg. This target (compared to mean achieved of 105 mmHg was associated with a 30% reduction in main CV events. In diabetes – Diastolic< or = 80mmhg 51 % lower risk compared to 90 mmHg
Slide 7 - Kieran McGlade Nov 2001 Department of General Practice QUB
Slide 8 - Kieran McGlade Nov 2001 Department of General Practice QUB Hypertension and Diabetes Hypertension co-exists with type II in about 40% at age 45 rising to 60% at age 75. 70% of type II patients die from cardio-vascular disease. At least 60% of patients will require 2 or 3 antihypertensive agents to achieve tight control.
Slide 9 - Kieran McGlade Nov 2001 Department of General Practice QUB Stages Identification of hypertensive patients Baseline investigations Initiating therapy Reviewing patients Stepping up therapy Motivation and compliance
Slide 10 - Kieran McGlade Nov 2001 Department of General Practice QUB Investigation of the New Hypertensive History and examination Exclude secondary Hypertension Urea and electrolytes FBP and ESR ECG Lipid profile Chest x-ray no longer routinely indicated
Slide 11 - Kieran McGlade Nov 2001 Department of General Practice QUB Clinical clues to renal vascular disease Hypertension under 50 Yrs of age. Generalised vascular (esp peripheral) disease. Mild – moderate renal dysfunction. Sudden onset pulmonary oedema.
Slide 12 - Kieran McGlade Nov 2001 Department of General Practice QUB Ladder Approach Bendrofluazide Bendrofluazide + Atenolol or ACE Calcium Channel blocker Alpha blocker
Slide 13 - Kieran McGlade Nov 2001 Department of General Practice QUB Tailored Approach Assessment of overall cardiovascular risk Recognition of co-morbidities Lipid profile Renal function Existing contra- indications
Slide 14 - Kieran McGlade Nov 2001 Department of General Practice QUB
Slide 15 - Kieran McGlade Nov 2001 Department of General Practice QUB Coronary Risk Calculator Launch risk calculator program
Slide 16 - Kieran McGlade Nov 2001 Department of General Practice QUB Compelling and possible indications and contrindications for the major classes of antihypertensive drugs                                 INDICATIONS               CONTRAINDICATIONS *  ACE inhibitors may be beneficial in chronic renal failure but should be used with caution. Close supervision and specialist  advice are needed when there is established and significant renal impairment †   Caution with ACE inhibitors and angiotensin II receptor antagonists in peripheral vascular disease because of association         with renovascular disease. ‡   If ACE inhibitor indicated f  b-blockers may worsen heart failure, but in specialist hands may be used to treat heart failure  British Hypertension Society Guidelines 2000
Slide 17 - Kieran McGlade Nov 2001 Department of General Practice QUB Therapeutic targets Therapeutic targets *                           Measured in clinic               Mean daytime ABPM                                                                     or home measurement Blood Pressure            No diabetes      Diabetes                No diabetes        Diabetes Optimal                         <140/85           <140/80                  <130/80              <130/75 Audit Standard             <150/90             <140/85                  <140/85              <140/80     The audit standard reflects the minimum recommended levels of BP control.  Despite best practice, it may not be achievable in some treated hypertensive patients. NB: Both systolic and diastolic targets should be reached British Hypertension Society Guidelines
Slide 18 - Kieran McGlade Nov 2001 Department of General Practice QUB Logical Combinations * Verapamil + beta-blocker = absolute contra-indication
Slide 19 - Kieran McGlade Nov 2001 Department of General Practice QUB ACE Inhibitor Side Effects Cough (15% of patients. Is reversible) Taste disturbance (reversible) Angiodema First-dose hypotension Hyperkalaemia ( esp. in patients with type II diabetes and renal dysfunction)
Slide 20 - Kieran McGlade Nov 2001 Department of General Practice QUB Follow-up For patients with BP stabilised by management, follow up should normally be three monthly (interval should not exceed 6 months), at which the following should be assessed by a trained nurse: *   Measurement of BP and weight  *   Reinforcement of non-pharmacological advice *   General health and drug side-effects  *   Test urine for proteinuria (annually)
Slide 21 - Kieran McGlade Nov 2001 Department of General Practice QUB Web based references British Hypertension Society: http://www.hyp.ac.uk/bhs/ Summary Guidelines 2000:http://www.hyp.ac.uk/bhs/gl2000.htm Hypertension audit protocol from Leicesterhttp://www.le.ac.uk/genpractice/gpaudit/htnprot.html
Slide 22 - Kieran McGlade Nov 2001 Department of General Practice QUB Drug Treatment of Essential Hypertension in Older People Hypertension is very common, occuring in over 50% of older people, and is a major risk factor for stroke and ischaemic heart disease. Drug treatment of hypertension in older people saves lives and prevents unnecessary morbidity. Treating isolated systolic hypertension also saves lives.
Slide 23 - Kieran McGlade Nov 2001 Department of General Practice QUB Drug Treatment of Essential Hypertension in Older People There is strong evidence to support the use of diuretics as first-line agents. Antihypertensive treatments are most cost-effective when targeted at older patients. There is evidence of under detection and under treatment of hypertension. Factors influencing patient adherence with treatment are not well understood and require further research.
Slide 24 - Kieran McGlade Nov 2001 Department of General Practice QUB RECOMMENDATIONS (for the treatment of the elderly) Through the wider use of antihypertensive therapies more older people would be able to maintain a healthy and active lifestyle. Through the wider use of antihypertensive therapies more older people would be able to maintain a healthy and active lifestyle. For first-line agents there is strong evidence to support the use of diuretics and some evidence for the use of beta-blockers. Systems to ensure that older people with hypertension are diagnosed, treated and followed up need to be developed. A system of audit should be cultivated to assure adequate treatment. High quality research on patient adherence with antihypertensive medications is needed. NHS Centre for reviews and dissemination 1999
Slide 25 - Kieran McGlade Nov 2001 Department of General Practice QUB Practical Points 15 – 20% of adult western population. Isolated systolic hypertension just as dangerous. Primary cause identified in only 5%. Investigate – Urine, FBP, ESR, ECG, U&E, Lipids. Target < 140/85. Bendrofluazide 2.5 mg a good starting point. Refer patients needing more than 3 drugs to control their hypertension.